Solriamfetol: A Promising Off-Label Treatment for Adult ADHD
Living with ADHD can be challenging, but at Philadelphia Integrative Psychiatry, Dr. Danish and his team are committed to providing innovative and personalized care. One of the promising treatments we explore is solriamfetol, a medication originally approved for both narcolepsy and Obstructive Sleep Apnea (OSA), which has shown significant potential in managing ADHD symptoms in adults.
A recent study titled “Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study” investigates the efficacy and safety of solriamfetol for adult ADHD. This blog highlights the key findings from this research and discusses how it aligns with our integrative approach to mental health care.
Efficacy of Solriamfetol in Managing ADHD
The study conducted by Surman and colleagues involved a 6-week trial with 60 adults diagnosed with ADHD. Participants were randomized to receive either solriamfetol or a placebo. Results showed that those taking solriamfetol experienced a significantly greater reduction in ADHD symptoms compared to the placebo group, as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS). By week 6, 28% of participants on solriamfetol improved their AISRS scores by 50%, compared to only 3% in the placebo group.
Favorable Side Effect Profile
Solriamfetol was well-tolerated among participants, with most adverse effects being mild or moderate. Common side effects included decreased appetite, headache, nausea, and insomnia. Importantly, there were no significant differences in vital sign changes between the solriamfetol and placebo groups, indicating a favorable safety profile.
In other studies, the 10 most common side effects of solriamfetol include insomnia, anxiety, nausea, decreased appetite, headache, irritability, fast or pounding heartbeats, blurred vision, excessive sweating, and dry mouth.
Dosing Information
The dose range for solriamfetol in both narcolepsy and OSA goes up to 150mg daily. For ADHD, participants were initially given a dose of 75 mg of solriamfetol, which could be adjusted to 112.5 or 150 mg based on tolerability and efficacy. The goal was to maintain stable dosing during the last four weeks of the study. This flexibility in dosing helps tailor treatment to individual patient needs while minimizing adverse effects.
Conclusion & Getting in Touch with Dr. Danish and His Team
In managing ADHD, Dr. Danish emphasizes the need for innovative and multifaceted approaches, particularly given the challenges many patients face with traditional stimulant medications. At Philadelphia Integrative Psychiatry, we recognize that stimulants are not always well-tolerated, and non-stimulant options can sometimes fall short in effectiveness. This is why our practice is dedicated to exploring a range of treatments, including cutting-edge therapies like solriamfetol, which offers a promising alternative with its favorable side effect profile. By integrating advanced techniques such as neurofeedback, biofeedback, and personalized medication management, we strive to provide comprehensive care that addresses the unique needs of each patient. Our commitment to innovation ensures that we remain at the forefront of psychiatric care, offering hope and improved outcomes for those living with ADHD and other mental health disorders. If you or a loved one are seeking support for ADHD or similar challenges, please text or call 610-999-6414 to learn how we can help.
For More on This Topic and Related Subjects, Check Out These Blogs by Dr. Danish:
https://phillyintegrative.com/blog/anxiety-relief-in-adhd-patients-with-stimulant-treatment
https://phillyintegrative.com/blog/embracing-the-strengths-of-adhd-insights-from-the-successful-and-famous
Sources
